Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · March 14, 2023

Recommended and Prevalent Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors in a National Population-Based Sample

Annals of Internal Medicine


Additional Info

Annals of Internal Medicine
Recommended and Prevalent Use of Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in a National Population-Based Sample
Ann. Intern. Med 2023 Feb 28;[EPub Ahead of Print], S Tang, H Shao, MK Ali, P Zhang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading